ASP3652 + Gemfibrozil + Repaglinide
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Drug Interaction (DDI)
Conditions
Drug-Drug Interaction (DDI), Healthy Subjects
Trial Timeline
Apr 1, 2012 → Jun 1, 2012
NCT ID
NCT01797198About ASP3652 + Gemfibrozil + Repaglinide
ASP3652 + Gemfibrozil + Repaglinide is a phase 1 stage product being developed by Astellas Pharma for Drug-Drug Interaction (DDI). The current trial status is completed. This product is registered under clinical trial identifier NCT01797198. Target conditions include Drug-Drug Interaction (DDI), Healthy Subjects.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01797198 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-Drug Interaction (DDI)